Study on the Effect of Granisetron on Myofascial Pain in the Orofacial Muscles
CompletedPhase 4NCT02230371
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The aim of this study is to to investigate if local treatment with intramuscular injections of granisetron are effective in alleviating pain in patients with chronic myofascial pain in the orofacial muscles The study hypothesis is that local administration of granisetron reduces pain and allodynia/hyperalgesia in patients with chronic myofascial pain in the orofacial muscles and that this effect of granisetron on pain is larger than the effect from placebo
Study details
- Official title
- The Serotonin Receptor Type 3 Antagonist Granisetron as a New Treatment Approach for Patients With Chronic Myofascial Pain in the Orofacial Muscles
- Conditions
- Myofascial Pain
- Temporomandibular Disorders
- Interventions
- Drug: Granisetron
- Drug: Control (placebo)
- Sponsor
- Karolinska Institutet
- Collaborators
- Folktandvården Stockholms län AB
- Start date
- 2007-03
- Primary completion
- 2014-10
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Sweden
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * age ≥ 18 years * a diagnosis of myofascial pain according to the research diagnostic criteria for TMD Axis I (RDC/TMD) * duration of TMD pain ≥ 3 months * self-assessed average myofascial-TMD pain intensity of ≥ 30 mm on a 100-mm visual analogue scale (VAS) during one week prior to examination * familiar pain upon digital palpation of the masseter and/or the temporalis muscles. * The patients remain included with one or several co-diagnoses of; a) disc displacement with or without reduction, b) osteoarthrosis in the any of the temporomandibular joints (TMJ), and c) episodic or chronic tension type headache Exclusion Criteria: * diagnosed systemic muscular or joint diseases (e.g. fibromyalgia, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis) * whiplash associated disorder * neuropathic pain or neurological disorders (e.g. myasthenia gravis, orofacial dystonia) * history of psychiatric disorders * pain of dental origin * use of muscle relaxants or any medication that might influence the response to pain * pregnancy or lactation * known hypersensitivity to granisetron
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02230371